Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

other applicable criteria for continued listing on The NASDAQ Capital Market, but for the $1.00 bid price requirement, which has been suspended by NASDAQ through August 2, 2009. If the application is approved, the company will no longer be subject to delisting from NASDAQ as a result of the previously disclosed stockholders' equity deficiency as of December 31, 2008, but it will need to comply with The NASDAQ Capital Markets' continued listing requirements on an ongoing basis.

Financial Highlights

  • Revenues for the three and six months ended June 30, 2009 were $3.5 million and $3.7 million compared to $2.6 million and $4.9 million for the same periods in 2008. Sunesis recognized $2.0 million in the second quarter of 2009 for the sale to SARcode of its interest in the lymphocyte function-associated antigen-1, or LFA-1, patents and related know-how that had previously been the subject of a license agreement with them, and $1.5 million for the Biogen Idec Raf kinase inhibitor milestone referred to above. Revenues in the 2008 periods were primarily related to research funding under the Biogen Idec collaboration.
  • Research and development expenses decreased to $3.4 million and $7.7 million for the three and six months ended June 30, 2009 from $8.3 million and $17.0 million for the same periods in 2008. The decreases were primarily due to savings from the termination of substantially all discovery research activities in June 2008.
  • General and administrative expenses for the first three and six months of 2009 were $2.0 million and $4.3 million compared to $3.2 million and $6.5 million for the same periods in 2008. The decreases were primarily due to reduced administrative headcount and facility costs as a result of the company's June 2008 and March 2009 restructurings.
  • Restructuring charges of $1.9 million were recorded in the first half o
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... WI (PRWEB) May 24, 2013 ... the discovery and development of calcium-binding proteins to ... of safety assessment study of apoaequorin ... international journal published for the British Industrial Biological ... study was to investigate potential adverse effects, if ...
(Date:5/23/2013)... Can economic incentives such as gift ... of the public to increase their donations of blood? ... Carey Business School Assistant Professor Mario Macis says ... large body of recent research that supports their argument, ... issue of Science that the World Health Organization and ...
(Date:5/23/2013)... The maker community is a contemporary group ... focus on learning practical skills while applying them creatively ... their ideas to life via crowdfunding. A subgroup within ... projects using biology. Glowing Plant has worked for months ... glow with bioluminescence genes, and has now pursued crowdfunding ...
(Date:5/23/2013)... , May 23, 2013 BioTrends ... and advisory firms for specialized biopharmaceutical issues, finds ... and infectious disease specialists reported that in the ... (e.g., intentionally delaying treatment) in anticipation of the ... six months ago, when only 6 percent reported ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... by researchers at the Swedish medical university Karolinska Institutet ... the "bad" LDL cholesterol and thereby cause an inflammation ... the T cell receptors, the researchers have managed to ... is presented online in the distinguished periodical Journal ...
... 4:30 p.m. Eastern Time , , , ... May 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ) ... the Company,s highlights for the first quarter of 2010. , , ... , , ...
... China , May 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China ... pharmaceutical company in the People,s Republic of China ,("PRC"), today announced that ... (EDT) on Tuesday, May 11, 2010 , to discuss its first,quarter of ... ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6OncoGenex Reports First Quarter Financial Results 7OncoGenex Reports First Quarter Financial Results 8OncoGenex Reports First Quarter Financial Results 9China Sky One Medical Announces Conference Call to Discuss First Quarter 2010 Results 2China Sky One Medical Announces Conference Call to Discuss First Quarter 2010 Results 3
(Date:5/23/2013)... at Emory University, along with partners at the ... million grant over four years to establish the ... Research Center: Understanding Lifetime Exposures). The grant is ... United States. , The HERCULES Center is ... Sciences (NIEHS) of the National Institutes of Health ...
(Date:5/23/2013)... implications for the overall health, development, and academic ... role in ensuring that all students have opportunities ... day of vigorous or moderate-intensity physical activity, says ... Recent estimates suggest that only about half ... promoting better health and development. The report ...
(Date:5/23/2013)... in treating cerebral palsy with autologous cord blood. Following ... year old boy had been in a persistent vegetative ... months after treatment with the cord blood containing stem ... the child learned to speak simple sentences and to ... study, dispel the long-held doubts about the effectiveness of ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... New Haven, Conn.Yale University engineers have for the first ... a feat they accomplished using fluorescence microscopy. The team ... Journal of Biomedical Optics , in a study ... technique called multiphoton microscopy with "optical clearing," which uses ...
... and under-diagnosed genetic disease in humans just may be ... College of Georgia researchers report. They are pursuing a ... wet form of macular degeneration, the leading cause of blindness ... iron, known to wreak cumulative havoc on the body,s organs, ...
... deep ocean animal communities can undergo rapid, widespread and ... are at the forefront of monitoring these changes and ... in a special issue of the journal Deep ... the deep ocean floor as stable, relatively unvarying environment ...
Cached Biology News:Scientists create 3-D models of whole mouse organs 2Link between iron overload and macular degeneration under study 2Link between iron overload and macular degeneration under study 3Ecological change in the abyss -- the Amperima event 2Ecological change in the abyss -- the Amperima event 3
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 50 mm x 50 ...
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
... (PR) Competitor Assay Kits are ideal ... receptor binding compounds using fluorescence polarization ... fusion of glutathione transferase to the ... receptor [PR-LBD(GST)] and a proprietary, fluorescently ...
... Eastman Kodak Companys Molecular Imaging Systems ... Image Station 4000 Digital Imaging Systems, ... technology for comprehensive fluorescence, luminescence, radiographic ... 4 million pixel CCD and 10x ...
Biology Products: